PREEMPTIVE RITUXIMAB IN ADAMTS13 RELAPSE DURING CLINICAL REMISSION OF IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A MULTICENTER ITALIAN STUDY (SIE 2026) - Oct 6, 2026 - Abstract #DP040; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "Predictors of biochemical relapse included prior RTX or caplacizumab use, prior clinical relapse, RTX dose and 12-months ADAMTS13 kinetics. Pts with a refractory/relapsing disease are at high- er relapse risk after preemptive RTX. Early ADAMTS13 ac- tivity dynamics identify pts who may benefit from intensified preemptive therapy, reinforcing the value of systematic ADAMTS13 monitoring."
Clinical • Hematological Disorders • Infectious Disease • Thrombocytopenia • Thrombocytopenic Purpura • ER
|
|
A. Dedola1,2; G. Carli3; C. Sartor1; B. Scappini4; B. Cambò5; G. Marchesini3; A. Dizdari6; S. Pozzi7; P. Bernuzzi8; A. Merli9; C. Lucarelli4; F. Salvatore1,2; D. Cavallina1,2; N. Severi1,2; F. Branzanti2; F. Lanza6; A. Lucchesi10; F. Palandri1
|